Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Recombinant Nonavalent HPV Vaccine in Healthy Indonesian Women
NCT06207175Phase 3Active, not recruiting
- Sponsor
- Beijing Health Guard Biotechnology Inc.
- Start
- Nov 2023
- Primary completion
- Nov 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, sponsored by Beijing Health Guard Biotechnology Inc.. Started Nov 2023; status: active, not recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT06207175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06207175.